1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Withdrawn 1 |
Follow MGGM LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of REL-1017 As Adjunctive Treatment of Major Depressive Disorder (MDD) REL1017 (esmethadone HCI) (active drug), Placebo - Major Depressive Disorder (MDD) | Phase 3 | Withdrawn | MGGM LLC | 2024-12-27 | 2025-02-07 |
Depressive Disorder, Major (1)
Italy (1) · Switzerland (1)